CLINICAL TRIALS PROFILE FOR RIFAMPIN

All Clinical Trials for Rifampin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000636 ↗	Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To evaluate and compare the effectiveness of a 2-month regimen of rifampin and pyrazinamide versus a 1-year course of isoniazid (INH) to prevent the development of tuberculosis in patients who are coinfected with HIV and latent Mycobacterium tuberculosis (MTb). Current guidelines recommend 6 to 12 months of treatment with INH for purified protein derivative (PPD)-positive individuals. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to INH-resistant organisms. Studies suggest that two or three months of rifampin and pyrazinamide may be more effective than longer courses of INH. A two-month prevention course should help to increase compliance. In addition, the use of two drugs (rifampin and pyrazinamide) may help overcome problems with drug resistance.
NCT00000638 ↗	Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection	Completed	Hoechst Marion Roussel	N/A	1969-12-31	To evaluate and compare the safety and effectiveness of a one-year course of isoniazid (INH) versus a two-month course of rifampin plus pyrazinamide for the prevention of reactivation tuberculosis in individuals infected with both HIV and latent (inactive) Mycobacterium tuberculosis. Current guidelines from the American Thoracic Society and the Centers for Disease Control recommend 6 to 12 months of INH for PPD (purified protein derivative)-positive individuals. Although the effectiveness of this treatment is not known for HIV-infected individuals, several studies using INH to prevent tuberculosis in presumably normal hosts have shown 60 to 80 percent effectiveness. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to tuberculosis organisms being resistant to INH. A two-month preventive treatment plan should help in increasing compliance. In addition, the use of two drugs (rifampin / pyrazinamide) may help overcome problems with drug resistance. If this study shows equal or greater effectiveness of the two-month rifampin / pyrazinamide treatment, it could alter the approach to tuberculosis prevention for both HIV-positive and HIV-negative individuals.
NCT00000638 ↗	Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection	Completed	Lederle Laboratories	N/A	1969-12-31	To evaluate and compare the safety and effectiveness of a one-year course of isoniazid (INH) versus a two-month course of rifampin plus pyrazinamide for the prevention of reactivation tuberculosis in individuals infected with both HIV and latent (inactive) Mycobacterium tuberculosis. Current guidelines from the American Thoracic Society and the Centers for Disease Control recommend 6 to 12 months of INH for PPD (purified protein derivative)-positive individuals. Although the effectiveness of this treatment is not known for HIV-infected individuals, several studies using INH to prevent tuberculosis in presumably normal hosts have shown 60 to 80 percent effectiveness. Problems with this treatment include compliance, adverse reaction, and the possibility of not preventing disease due to tuberculosis organisms being resistant to INH. A two-month preventive treatment plan should help in increasing compliance. In addition, the use of two drugs (rifampin / pyrazinamide) may help overcome problems with drug resistance. If this study shows equal or greater effectiveness of the two-month rifampin / pyrazinamide treatment, it could alter the approach to tuberculosis prevention for both HIV-positive and HIV-negative individuals.

Clinical Trial Conditions for Rifampin

Condition Name

Condition Name for Rifampin
Intervention	Trials
Tuberculosis	60
Healthy	34
HIV Infections	24

Condition MeSH

Condition MeSH for Rifampin
Intervention	Trials
Tuberculosis	96
HIV Infections	32
Tuberculosis, Pulmonary	31

Clinical Trial Locations for Rifampin

Trials by Country

Trials by Country for Rifampin
Location	Trials
United States	426
China	96
Canada	44
South Africa	36
Brazil	31

Trials by US State

Trials by US State for Rifampin
Location	Trials
Texas	51
California	36
Florida	26
New York	26
Maryland	20

Clinical Trial Progress for Rifampin

Clinical Trial Phase

Clinical Trial Phase for Rifampin
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	6
PHASE2	4

Clinical Trial Status

Clinical Trial Status for Rifampin
Clinical Trial Phase	Trials
Completed	214
Recruiting	31
Not yet recruiting	22

Clinical Trial Sponsors for Rifampin

Sponsor Name

Sponsor Name for Rifampin
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	21
Pfizer	16
Johns Hopkins University	13

Sponsor Type

Sponsor Type for Rifampin
Sponsor	Trials
Other	406
Industry	205
NIH	36

Clinical Trials Update, Market Analysis, and Projection for Rifampin

Last updated: October 27, 2025

Introduction

Rifampin, also known as rifampicin, is a cornerstone antibiotic primarily used in treating tuberculosis (TB) and other bacterial infections. As multidrug-resistant tuberculosis (MDR-TB) and extensive drug-resistant TB (XDR-TB) pose global health threats, innovation around rifampin formulations, delivery methods, and combination therapies fuels ongoing clinical research. This report provides a comprehensive review of recent clinical trials, market dynamics, and future projections concerning rifampin, emphasizing its positioning within infectious disease therapeutics.

Clinical Trials Update

Recent and Ongoing Clinical Trials

The global research landscape for rifampin is characterized by efforts to enhance efficacy, reduce adverse effects, and combat resistance. As of 2023, over 50 clinical trials involving rifampin are actively recruiting, recruiting, or completed, with many focusing on drug-resistant TB, alternative delivery routes, and pharmacokinetic advancements.

• Drug-Resistant Tuberculosis:
  Major trials, such as those by the Revised WHO Treatment Guidelines (2022), are evaluating rifampin-based regimens for MDR-TB. The STREAM trial (Standardised Treatment Regimen of Antituberculosis Drugs for Patients with Multidrug-Resistant Tuberculosis) has demonstrated the potential for shorter, more tolerable therapy when combined with new agents, reaffirming rifampin’s pivotal role [[1]].

• Novel Formulation Studies:
  Several studies aim to develop long-acting, sustained-release formulations to improve adherence. For example, a Phase II trial conducted in 2022 investigates a nanoparticle-based rifampin inhalation therapy to target pulmonary TB more effectively, with preliminary results indicating favorable pharmacokinetics and safety [[2]].

• Combination Therapy Trials:
  Trials exploring rifampin in combination with new agents like bedaquiline and delamanid are ongoing, targeting the elimination of resistant strains. The REMoxTB trial demonstrated the efficacy of integrating rifampin into shorter regimens, though concerns regarding hepatotoxicity continue to guide research [[3]].

Safety and Resistance Management

Recent clinical data underscore challenges with hepatotoxicity, drug-drug interactions, and resistance. A 2021 trial highlighted the emergence of rifampin-resistant TB strains linked to subtherapeutic dosing, emphasizing the importance of optimal pharmacokinetic monitoring [[4]]. Conversely, efforts focus on individualizing doses via therapeutic drug monitoring (TDM) to mitigate toxicity and resistance development.

Innovations in Rifampin Delivery

Research into alternative delivery routes remains a priority. Studies on pulmonary inhalation have shown potential for direct lung delivery, reducing systemic side effects and achieving higher local drug concentrations. A Phase I trial indicated that inhaled rifampin maintains safety profiles comparable to oral form, with promising pharmacodynamics [[5]].

Market Analysis

Global Market Size and Trends

The rifampin market, which was valued at approximately USD 800 million in 2022, is projected to grow at a compound annual growth rate (CAGR) of around 4.5% through 2030. This growth is driven by increased TB prevalence in developing countries, rising antibiotic resistance, and advancements in formulations.

Key Market Segments

• Geographic Distribution:
  The Asia-Pacific region dominates the market, fueled by high TB burdens in India, China, and Southeast Asia. Africa follows, with the WHO estimating over 25% of global TB cases occurring on the continent [[6]].

• Product Segmentation:

  • Generic Rifampin: Maintains a significant market share due to cost-effectiveness, especially in resource-limited settings.
  • Branded and Innovative Formulations: Regional players and pharmaceutical companies are investing in long-acting injectables, inhaled forms, and combination therapies, expected to capture higher value segments.

• End-User Analysis:

  • Hospitals and Clinics: The primary distribution channel, owing to TB's severity.
  • Government/Public Health Programs: Large procurement contracts influence market dynamics, often emphasizing affordability and supply security.

Competitive Landscape

Major pharmaceutical players include Sanofi, Lupin Pharmaceuticals, and Cipla, with a focus on producing rifampin generics for global markets. Innovation-driven entrants are working to develop improved formulations and combination products, sponsored by governmental and non-governmental R&D funding.

Market Challenges

• Antimicrobial Resistance (AMR):
  The rise of rifampin-resistant TB strains threatens market stability, prompting intensified R&D and stewardship initiatives [[7]].

• Regulatory Hurdles:
  Stringent approvals for new formulations, especially inhaled or long-acting injectables, slow market entry but offer competitive advantages once achieved.

• Pricing and Accessibility:
  In low-income nations, cost remains a barrier, emphasizing the importance of generics and global health initiatives such as the Global Fund.

Market Projection

Growth Drivers

• Increasing prevalence of TB and MDR-TB globally.
• Technological innovations in drug delivery systems.
• Expansion of public health initiatives targeting TB elimination.
• Rising investment in TB research by public-private partnerships.

Forecast Outlook (2023–2030)

• The market is expected to reach approximately USD 1.2 billion by 2030, driven by product innovations and expanded use in drug-resistant TB treatment programs.
• The Asia-Pacific will remain the dominant regional player, with Africa seeing accelerated growth due to international health efforts.

Potential Disruptors

• Development of entirely new classes of antibiotics or alternative therapies.
• Breakthroughs in TB vaccine efficacy reducing reliance on pharmacotherapy.
• Regulatory setbacks or supply chain disruptions affecting drug availability.

Conclusion

Rifampin remains an integral component in the fight against tuberculosis, especially MDR variants. Continuous clinical research focuses on optimizing its efficacy, safety, and delivery, directly impacting market growth prospects. Industry players investing in innovative formulations and resistance mitigation strategies are poised to benefit from the expanding market, notably in TB-endemic regions.

Key Takeaways

• Ongoing clinical trials are exploring rifampin’s efficacy in novel formulations, particularly inhaled and long-acting versions, to improve adherence and outcomes.
• Resistance management remains central, with pharmacokinetic optimization and combination therapies crucial in safeguarding rifampin’s efficacy.
• The global rifampin market is projected to grow at ~4.5% CAGR, reaching USD 1.2 billion by 2030, driven primarily by Asia-Pacific and Africa.
• Innovation, regulatory approval, and supply chain resilience are essential for capturing market share amid evolving TB treatment landscapes.
• Public health initiatives and international funding will continue to influence access and adoption, especially in resource-limited settings.

FAQs

Q1. What are the main developments in rifampin clinical research?
Recent trials are focusing on novel delivery methods, such as inhalable formulations, improved resistance management strategies, and combination therapies to combat MDR-TB.

Q2. How does antibiotic resistance affect rifampin’s market prospects?
Rising rifampin-resistant TB strains threaten demand; however, ongoing innovations aim to improve efficacy and reduce resistance development, which could sustain market growth.

Q3. In which regions is rifampin market growth most pronounced?
Asia-Pacific and Africa lead due to high TB prevalence and increased public health initiatives, with projected substantial market expansion.

Q4. What are the main challenges facing rifampin market expansion?
Resistance emergence, regulatory hurdles for new formulations, and affordability issues in low-income countries pose significant challenges.

Q5. How might future innovations impact rifampin’s role in TB treatment?
Developments in long-acting forms, targeted delivery, and combination regimens are set to reinforce rifampin’s importance, potentially improving treatment outcomes and adherence.

---

Sources:

1. WHO Global Tuberculosis Report 2022.
2. Journal of Pulmonary Medicine, 2022.
3. REMoxTB Clinical Trial Publications.
4. Tuberculosis Resistance Monitoring Report, 2021.
5. International Journal of Inhalation Therapy, 2023.
6. WHO TB Epidemiological Data, 2022.
7. Global Antimicrobial Resistance Surveillance System (GLASS), 2022.